112,904 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 112,904 shares of the company's stock, valued at approximately $629,000. Raymond James Financial Inc. owned 0.24% of 4D Molecular Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of FDMT. Rhumbline Advisers raised its holdings in 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after buying an additional 3,675 shares during the last quarter. Proficio Capital Partners LLC increased its position in shares of 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after acquiring an additional 10,000 shares during the period. Y Intercept Hong Kong Ltd raised its stake in shares of 4D Molecular Therapeutics by 81.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company's stock valued at $265,000 after acquiring an additional 11,002 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of 4D Molecular Therapeutics during the third quarter worth about $166,000. Finally, M&T Bank Corp grew its stake in shares of 4D Molecular Therapeutics by 98.9% in the fourth quarter. M&T Bank Corp now owns 37,487 shares of the company's stock worth $209,000 after purchasing an additional 18,639 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Bank of America decreased their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. Leerink Partners cut their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a report on Monday, January 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday. Finally, Royal Bank of Canada dropped their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.71.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded up $0.04 during trading on Friday, hitting $2.63. The company's stock had a trading volume of 822,218 shares, compared to its average volume of 827,361. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $28.93. The company has a market capitalization of $121.77 million, a PE ratio of -0.92 and a beta of 2.89. The company has a fifty day simple moving average of $4.04 and a two-hundred day simple moving average of $6.13.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10). As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.